UNSPSC 51172105: Phloroglucinol

This classification denotes an indicator, reagent, antispasmodic, and trinitrobenzene with the molecular formula C6H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DHD7FFG6YS, chemically known as 1,3,5-triol but generally known as phloroglucinol, which bears US NIH Compound Identifier 359. European Medicines Agency schedules Phloroglucinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14845MIG.

World Health Organization schedules phloroglucinol in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, PHLOROGLUCINOL remains the US FDA Preferred Term for this commodity. SMILES: OC1CC(O)CC(O)C1.

UNSPSC 51172105 Phloroglucinol (Commodity) encompasses pharmaceutical and chemical products procured by state and local health, corrections, and human services agencies, though recent solicitations show minimal direct procurement of phloroglucinol itself. Instead, state and local buyers soliciting under this code are acquiring broader pharmaceutical supply chains, drug testing services, and multi-source generic and over-the-counter medication programs. Issuing bodies include state health and human services departments, county corrections and community supervision agencies, and state-administered cooperative purchasing alliances. The work ranges from specimen collection and drug screening operations with lab certification requirements to wholesale pharmaceutical distribution agreements requiring cGMP compliance, DSCSA certification, and multi-wholesaler channel management.

Texas dominates recent activity: Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services with an estimated contract value of $600,000 and a two-year initial term commencing September 1, 2026, plus three optional one-year renewals. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted March 27, 2026, response deadline April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. Minnesota's Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP posted January 20, 2026 (due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed to participating state and local facilities across Minnesota and Oregon, effective July 1, 2026, with contract terms through June 30, 2028 for incumbent responders. All three opportunities carry mandatory compliance certifications—SAMHSA, state DPS, or CAP lab certification for testing; cGMP and DSCSA for pharmaceutical manufacturing and distribution. The code shows sparse direct activity in phloroglucinol procurement specifically; the three recent opportunities reflect state and local demand for broader pharmaceutical logistics, testing infrastructure, and multi-jurisdictional generic medication supply rather than a standalone chemical commodity.